ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.532
AS - Asia 11.101
EU - Europa 6.848
SA - Sud America 1.880
AF - Africa 226
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 17
Totale 43.643
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.246
SG - Singapore 3.728
HK - Hong Kong 2.759
CN - Cina 2.619
GB - Regno Unito 1.721
BR - Brasile 1.504
SE - Svezia 1.050
IT - Italia 885
VN - Vietnam 764
RU - Federazione Russa 691
DE - Germania 553
BG - Bulgaria 359
PL - Polonia 334
FI - Finlandia 237
FR - Francia 213
ID - Indonesia 188
KR - Corea 181
AR - Argentina 177
TR - Turchia 141
IN - India 137
CA - Canada 134
UA - Ucraina 129
NL - Olanda 121
JP - Giappone 104
AT - Austria 97
MX - Messico 95
BD - Bangladesh 86
ZA - Sudafrica 75
LT - Lituania 72
ES - Italia 63
IE - Irlanda 63
IQ - Iraq 55
EC - Ecuador 52
CZ - Repubblica Ceca 45
EG - Egitto 43
AE - Emirati Arabi Uniti 39
CO - Colombia 37
BE - Belgio 36
MA - Marocco 34
SA - Arabia Saudita 32
RO - Romania 31
UZ - Uzbekistan 30
PK - Pakistan 27
CL - Cile 26
PY - Paraguay 26
AU - Australia 25
MY - Malesia 21
IL - Israele 20
VE - Venezuela 20
JO - Giordania 19
TN - Tunisia 19
IR - Iran 18
PE - Perù 18
GR - Grecia 16
KE - Kenya 16
KZ - Kazakistan 15
NO - Norvegia 15
A2 - ???statistics.table.value.countryCode.A2??? 14
PH - Filippine 14
CH - Svizzera 13
AL - Albania 12
AZ - Azerbaigian 12
KG - Kirghizistan 12
NP - Nepal 12
PT - Portogallo 12
UY - Uruguay 12
MK - Macedonia 11
NZ - Nuova Zelanda 11
DO - Repubblica Dominicana 10
DZ - Algeria 10
LV - Lettonia 10
HN - Honduras 9
DK - Danimarca 8
MD - Moldavia 8
ET - Etiopia 7
GE - Georgia 7
LB - Libano 7
BH - Bahrain 6
BO - Bolivia 6
BY - Bielorussia 6
CR - Costa Rica 6
EE - Estonia 6
HU - Ungheria 6
LA - Repubblica Popolare Democratica del Laos 6
SK - Slovacchia (Repubblica Slovacca) 6
KH - Cambogia 5
RS - Serbia 5
TH - Thailandia 5
AM - Armenia 4
BW - Botswana 4
BZ - Belize 4
CY - Cipro 4
GD - Grenada 4
IS - Islanda 4
LK - Sri Lanka 4
LU - Lussemburgo 4
PA - Panama 4
TW - Taiwan 4
HR - Croazia 3
JM - Giamaica 3
Totale 43.581
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.393
Hong Kong 2.728
Singapore 2.449
Fairfield 2.372
Ashburn 2.176
Chandler 2.080
London 972
Nyköping 857
Woodbridge 848
New York 830
Houston 775
Wilmington 753
Hefei 706
Seattle 697
Cambridge 624
Los Angeles 494
Ann Arbor 475
San Diego 465
Beijing 437
Chicago 390
Princeton 372
Sofia 356
Southend 344
Warsaw 320
Ho Chi Minh City 275
The Dalles 226
Moscow 217
Helsinki 196
Buffalo 179
Shanghai 178
Jersey City 175
Hanoi 166
Modena 165
Seoul 164
Dearborn 152
Salt Lake City 149
Jakarta 146
Jacksonville 143
São Paulo 143
Council Bluffs 136
Redondo Beach 113
Dallas 102
Bremen 86
Tokyo 80
Tampa 66
Munich 65
Denver 64
Milan 64
Vienna 63
Frankfurt am Main 61
Elk Grove Village 59
Dublin 58
Orem 58
Phoenix 58
Norwalk 56
Rome 55
Bologna 54
Brooklyn 53
Nuremberg 51
Viroflay 51
Izmir 48
Stockholm 47
Montreal 45
Rio de Janeiro 45
San Francisco 45
Kent 44
Kilburn 44
Atlanta 43
Augusta 43
Guangzhou 43
Toronto 42
Grafing 41
Des Moines 40
Johannesburg 40
Poplar 38
Sterling 36
Amsterdam 35
Brussels 35
Istanbul 35
San Mateo 35
Boston 34
Brno 33
Paris 33
Curitiba 32
Biên Hòa 31
Da Nang 30
Eugene 30
Detroit 29
Haiphong 29
Chennai 28
Chiswick 28
Groningen 27
Lauterbourg 27
Mexico City 27
Lancaster 26
Belo Horizonte 25
Portsmouth 25
Tashkent 25
Ankara 24
Düsseldorf 24
Totale 31.431
Salva come PNG Salva come JPEG
Nome #
Non-alcoholic steatohepatitis and liver transplantation 453
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 357
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 356
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 331
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 289
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 285
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 283
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 275
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 271
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 266
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 263
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 258
Missed treatment in an Italian HBV infected patients cohort: HBV RER 253
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 249
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 248
From current status to optimization of HCV treatment: Recommendations from an expert panel 246
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 241
Treatment of nonalcoholic steatohepatitis in adults: present and future 237
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 226
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 217
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 216
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 215
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 214
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 213
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 210
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 207
Global multi-stakeholder endorsement of the MAFLD definition 205
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 203
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 202
Adaptive response in Hepatitis B virus infection 202
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 200
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 197
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 195
Characteristics of hepatocellular carcinoma in Italy 194
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 194
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 188
Update on Alcohol and Viral Hepatitis 185
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 183
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 179
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 175
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 172
Gross pathologic types of hepatocellular carcinoma in Italy. 172
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 171
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 170
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 169
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 169
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 168
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 167
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 167
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 165
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 163
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 162
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 162
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 161
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 157
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 157
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 155
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 155
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 155
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 153
Clinical and serological profile of primary biliary cirrhosis in men 153
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 152
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 151
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 151
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 151
Alcohol and viral hepatitis: a mini-review 148
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 146
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned 146
Chronic hepatitis B: Are we close to a cure? 146
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 146
Indomethacin increases 2′,5′-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis 144
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 144
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 143
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 143
Virological Treatment Monitoring for Chronic Hepatitis B 142
Central pontine myelinolysis secondary to glycemic variability in type 1 diabetes: a case report and a systematic review of the literature 142
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 142
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 142
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 142
Frailty after Liver Transplantation: A Complex Unexplored Issue 140
CD 133+ stem cells for the treatment of end stage liver disease 140
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 139
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 138
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 138
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 138
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 138
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 138
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 137
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence 136
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 136
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 136
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 135
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 135
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C 134
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 134
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 133
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 132
A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. 132
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis 132
Comparing and combining gamma-hydroxybutiric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study 132
Totale 18.478
Salva come PNG Salva come JPEG
Categoria #
all - tutte 264.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 264.381
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.183 0 0 0 0 0 161 285 158 1.347 142 954 136
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202611.558 1.254 771 1.937 2.630 3.300 1.666 0 0 0 0 0 0
Totale 44.164